The purpose of this study is to evaluate the effectiveness of lebrikizumab in treating adults with moderate-to-severe Prurigo Nodularis (PN).
Age 18-80
Diagnosis of Prurigo Nodularis (PN) for at least 1 year
Active PN with moderate-to-severe itch, several nodules, and presence of nodules in more than one part of the body
Women of childbearing potential must agree to remain abstinent or use a highly effective contraceptive method during treatment and for at least 18 weeks after the last dose of study drug
Prior participation in a lebrikizumab study
History of anaphylaxis
History of or active HIV
Active hepatitis or known liver cirrhosis
University of Maryland, Baltimore
Lead sponsor
Eli Lilly and Company
Collaborator